EFTR [NASD]
eFFECTOR Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own25.32% Shs Outstand40.85M Perf Week-24.28%
Market Cap75.84M Forward P/E- EPS next Y-0.72 Insider Trans-3.86% Shs Float34.06M Perf Month-54.87%
Income15.80M PEG- EPS next Q-0.24 Inst Own72.20% Short Float0.70% Perf Quarter-64.29%
Sales1.40M P/S54.17 EPS this Y- Inst Trans2.14% Short Ratio9.79 Perf Half Y-82.16%
Book/sh0.62 P/B2.74 EPS next Y-127.50% ROA- Target Price18.68 Perf Year-82.56%
Cash/sh1.02 P/C1.66 EPS next 5Y- ROE- 52W Range1.65 - 40.42 Perf YTD-79.47%
Dividend- P/FCF- EPS past 5Y- ROI45.80% 52W High-95.79% Beta-
Dividend %- Quick Ratio18.40 Sales past 5Y- Gross Margin- 52W Low3.03% ATR0.31
Employees13 Current Ratio18.40 Sales Q/Q-25.60% Oper. Margin- RSI (14)17.10 Volatility12.27% 11.90%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.81 Prev Close1.70
ShortableYes LT Debt/Eq0.75 Earnings- Payout- Avg Volume24.24K Price1.70
Recom1.80 SMA20-37.43% SMA50-51.63% SMA200-78.95% Volume14,746 Change0.00%
Jan-25-22Downgrade Stifel Buy → Hold $20 → $6.20
Nov-09-21Upgrade Stifel Hold → Buy $20
Oct-12-21Initiated Credit Suisse Outperform $20
Oct-04-21Initiated Mizuho Buy $20
Sep-21-21Initiated JMP Securities Mkt Outperform $33
Sep-20-21Initiated Stifel Hold $20
Sep-13-21Initiated Cantor Fitzgerald Overweight $50
May-10-22 04:02PM  
May-03-22 06:45AM  
May-02-22 04:04PM  
Apr-04-22 08:30AM  
Mar-16-22 04:01PM  
Feb-16-22 08:30AM  
Feb-15-22 06:53PM  
Feb-09-22 04:00PM  
Jan-24-22 04:00PM  
Nov-24-21 08:00AM  
Nov-22-21 08:00AM  
Nov-08-21 07:00AM  
Nov-04-21 09:08AM  
Nov-01-21 04:05PM  
Oct-26-21 08:00AM  
Oct-07-21 04:30PM  
Sep-30-21 04:32PM  
Sep-16-21 08:00AM  
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Presidio Management Group X LL10% OwnerMay 16Sale1.7512,76922,295137,309May 16 06:36 PM
Presidio Management Group X LL10% OwnerMay 13Sale1.8422,60741,574137,704May 16 06:36 PM
Presidio Management Group X LL10% OwnerMay 12Sale2.0010,80021,632138,405May 16 06:36 PM
Presidio Management Group X LL10% OwnerMay 11Sale2.355,00011,725138,741May 11 08:10 PM
Presidio Management Group X LL10% OwnerMay 10Sale2.4139,98496,481138,896May 11 08:10 PM
Presidio Management Group X LL10% OwnerMay 09Sale2.544,00010,144140,137May 11 08:10 PM
Ehrlich Christopher BDirectorFeb 18Buy4.301,0004,30016,000Feb 22 04:59 PM
Ehrlich Christopher BDirectorFeb 14Buy4.452,0008,90015,000Feb 22 04:59 PM
Ehrlich Christopher BDirectorFeb 09Buy4.751,0004,75013,000Feb 10 05:05 PM
Ehrlich Christopher BDirectorFeb 08Buy4.921,0004,92012,000Feb 10 05:05 PM
Ehrlich Christopher BDirectorFeb 04Buy5.001,0005,00011,000Feb 07 09:00 AM
Ehrlich Christopher BDirectorFeb 03Buy5.155,00025,75010,000Feb 07 09:00 AM
Ehrlich Christopher BDirectorJan 27Buy5.305,00026,5155,000Jan 31 05:50 PM
ROOT JONATHAN DDirectorDec 02Sale5.688,11346,082140,261Dec 06 07:28 PM
Presidio Management Group X LL10% OwnerDec 02Sale5.688,11346,082140,261Dec 06 07:27 PM
ROOT JONATHAN DDirectorDec 01Sale6.4419,245123,880140,513Dec 01 06:31 PM
Presidio Management Group X LL10% OwnerDec 01Sale6.4419,245123,880140,513Dec 01 06:31 PM
Presidio Management Group X LL10% OwnerNov 30Sale6.5327,409179,036141,110Dec 01 06:31 PM
ROOT JONATHAN DDirectorNov 30Sale6.5327,409179,036141,110Dec 01 06:31 PM
ROOT JONATHAN DDirectorNov 29Sale6.7025,764172,490141,960Dec 01 06:31 PM
Presidio Management Group X LL10% OwnerNov 29Sale6.7025,764172,490141,960Dec 01 06:31 PM
Presidio Management Group X LL10% OwnerNov 26Sale7.015,02635,242142,759Nov 26 04:43 PM
ROOT JONATHAN DDirectorNov 26Sale7.015,02635,242142,759Nov 26 04:44 PM
ROOT JONATHAN DDirectorNov 24Sale7.3636,520268,605142,915Nov 26 04:44 PM
Presidio Management Group X LL10% OwnerNov 24Sale7.3636,520268,605142,915Nov 26 04:43 PM
Presidio Management Group X LL10% OwnerNov 23Sale7.4014,879110,150144,047Nov 26 04:43 PM
ROOT JONATHAN DDirectorNov 23Sale7.4014,879110,150144,047Nov 26 04:44 PM
Presidio Management Group X LL10% OwnerNov 22Sale7.8626,183205,798144,508Nov 22 07:12 PM
ROOT JONATHAN DDirectorNov 22Sale7.8626,183205,798144,508Nov 22 07:13 PM
ROOT JONATHAN DDirectorNov 19Sale8.127,24158,804145,320Nov 22 07:13 PM
Presidio Management Group X LL10% OwnerNov 19Sale8.127,24158,804145,320Nov 22 07:12 PM
Presidio Management Group X LL10% OwnerNov 18Sale8.5316,745142,801145,544Nov 22 07:12 PM
ROOT JONATHAN DDirectorNov 18Sale8.5316,745142,801145,544Nov 22 07:13 PM
ROOT JONATHAN DDirectorNov 17Sale9.1310,23593,415146,063Nov 17 07:56 PM
Presidio Management Group X LL10% OwnerNov 17Sale9.1310,23593,415146,063Nov 17 07:55 PM
Presidio Management Group X LL10% OwnerNov 16Sale9.428,31978,357146,380Nov 17 07:55 PM
ROOT JONATHAN DDirectorNov 16Sale9.428,31978,357146,380Nov 17 07:56 PM
ROOT JONATHAN DDirectorNov 15Sale9.815,07149,751146,637Nov 17 07:56 PM
Presidio Management Group X LL10% OwnerNov 15Sale9.815,07149,751146,637Nov 17 07:55 PM
Presidio Management Group X LL10% OwnerNov 12Sale10.0712,000120,840146,794Nov 12 05:52 PM
ROOT JONATHAN DDirectorNov 12Sale10.0712,000120,840146,794Nov 12 05:53 PM
ROOT JONATHAN DDirectorNov 11Sale10.3712,017124,592147,166Nov 12 05:53 PM
Presidio Management Group X LL10% OwnerNov 11Sale10.3712,017124,592147,166Nov 12 05:52 PM
Presidio Management Group X LL10% OwnerNov 10Sale10.4434,000354,824147,539Nov 12 05:52 PM
ROOT JONATHAN DDirectorNov 10Sale10.4434,000354,824147,539Nov 12 05:53 PM
ROOT JONATHAN DDirectorNov 09Sale11.0028,785316,750148,593Nov 12 05:53 PM
Presidio Management Group X LL10% OwnerNov 09Sale11.0028,785316,750148,593Nov 12 05:52 PM
EWTX Edgewise Therapeutics, Inc. daily Stock Chart
EWTX [NASD]
Edgewise Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own0.40% Shs Outstand49.55M Perf Week2.69%
Market Cap343.33M Forward P/E- EPS next Y-1.85 Insider Trans-5.40% Shs Float49.00M Perf Month-7.40%
Income-42.80M PEG- EPS next Q-0.33 Inst Own- Short Float7.98% Perf Quarter-44.96%
Sales- P/S- EPS this Y-216.90% Inst Trans0.07% Short Ratio18.53 Perf Half Y-64.22%
Book/sh5.25 P/B1.38 EPS next Y-24.80% ROA-17.50% Target Price25.00 Perf Year-73.88%
Cash/sh5.62 P/C1.29 EPS next 5Y- ROE-18.10% 52W Range6.93 - 29.98 Perf YTD-52.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.18% Beta-
Dividend %- Quick Ratio26.90 Sales past 5Y- Gross Margin- 52W Low7.36% ATR0.61
Employees38 Current Ratio26.90 Sales Q/Q- Oper. Margin- RSI (14)41.09 Volatility8.11% 7.56%
OptionableNo Debt/Eq0.00 EPS Q/Q-106.50% Profit Margin- Rel Volume0.97 Prev Close7.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume211.03K Price7.44
Recom1.30 SMA20-5.33% SMA50-17.31% SMA200-48.72% Volume154,050 Change2.48%
Apr-13-22Initiated RBC Capital Mkts Outperform $31
Jan-28-22Initiated Goldman Neutral $11
May-11-22 08:00AM  
May-03-22 08:00AM  
Apr-28-22 11:45AM  
Apr-14-22 08:00AM  
Mar-24-22 11:11AM  
Mar-08-22 08:00AM  
Feb-24-22 08:00AM  
Feb-03-22 04:35PM  
Feb-02-22 09:00AM  
Jan-10-22 07:40PM  
Jan-05-22 09:15AM  
08:00AM  
Dec-15-21 09:00AM  
Nov-17-21 09:00AM  
Nov-10-21 08:00AM  
Nov-04-21 11:23AM  
Oct-28-21 07:29AM  
06:00AM  
Oct-11-21 03:56PM  
Oct-06-21 11:45AM  
Oct-01-21 11:09AM  
Sep-25-21 09:57AM  
Sep-14-21 09:00AM  
Aug-16-21 09:00AM  
Aug-09-21 09:00AM  
Aug-04-21 09:00AM  
Jul-28-21 10:45AM  
Jun-27-21 05:12AM  
Jun-22-21 09:00AM  
Jun-01-21 09:00AM  
May-13-21 04:01PM  
May-04-21 09:00AM  
Apr-27-21 09:00AM  
Apr-16-21 07:31PM  
Mar-30-21 04:01PM  
08:06AM  
Mar-25-21 10:23PM  
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOORE JOHN RGeneral CounselMay 16Sale7.4210,80080,1463,000May 18 05:15 PM
MOORE JOHN RGeneral CounselJan 21Option Exercise0.715,4003,83412,362Jan 25 06:50 PM
MOORE JOHN RGeneral CounselDec 28Option Exercise0.715,4003,8346,962Dec 30 05:51 PM
Russell Alan JChief Scientific OfficerNov 30Option Exercise0.22172,58537,815172,585Dec 01 06:20 PM
Russell Alan JChief Scientific OfficerNov 15Sale19.114799,1550Nov 17 06:05 PM
Russell Alan JChief Scientific OfficerNov 12Sale19.518,562167,074479Nov 12 05:24 PM
Russell Alan JChief Scientific OfficerNov 11Sale19.9319,276384,2389,041Nov 12 05:24 PM
Russell Alan JChief Scientific OfficerNov 10Sale19.7312,326243,17028,317Nov 12 05:24 PM
Russell Alan JChief Scientific OfficerNov 09Sale20.0929,576594,30640,643Nov 12 05:24 PM
Russell Alan JChief Scientific OfficerNov 08Sale20.169,017181,82470,219Nov 08 07:11 PM
Russell Alan JChief Scientific OfficerNov 05Sale19.6213,042255,90779,236Nov 08 07:11 PM
Russell Alan JChief Scientific OfficerNov 04Sale19.767,392146,09292,278Nov 08 07:11 PM
Russell Alan JChief Scientific OfficerNov 03Sale18.1826,184476,09699,670Nov 03 07:00 PM
Russell Alan JChief Scientific OfficerNov 02Sale17.4317,519305,360125,854Nov 03 07:00 PM
Russell Alan JChief Scientific OfficerNov 01Sale18.024698,454143,373Nov 03 07:00 PM
Russell Alan JChief Scientific OfficerOct 15Sale18.121,43325,966143,842Oct 18 07:48 PM
Russell Alan JChief Scientific OfficerOct 14Sale18.185,749104,517145,275Oct 18 07:48 PM
Russell Alan JChief Scientific OfficerOct 11Sale18.021,27022,885151,024Oct 13 06:51 PM
Russell Alan JChief Scientific OfficerOct 08Sale18.155,902107,121152,294Oct 08 06:00 PM
Russell Alan JChief Scientific OfficerOct 07Sale18.5613,018241,614158,196Oct 08 06:00 PM
Russell Alan JChief Scientific OfficerOct 06Sale18.032,10838,007171,214Oct 08 06:00 PM
Russell Alan JChief Scientific OfficerOct 05Sale18.265,40498,677173,322Oct 05 06:33 PM
Russell Alan JChief Scientific OfficerOct 04Sale18.001001,800178,726Oct 05 06:33 PM
Russell Alan JChief Scientific OfficerOct 01Sale18.002744,932178,826Oct 05 06:33 PM
Russell Alan JChief Scientific OfficerSep 29Sale16.8611,844199,730179,100Sep 30 07:16 PM
Russell Alan JChief Scientific OfficerSep 28Sale17.3014,610252,753190,944Sep 30 07:16 PM
Russell Alan JChief Scientific OfficerSep 27Sale17.9811,611208,774205,554Sep 27 07:32 PM
Russell Alan JChief Scientific OfficerSep 24Sale18.1620,100365,016217,165Sep 27 07:32 PM
Russell Alan JChief Scientific OfficerSep 23Sale18.5426,835497,632237,265Sep 27 07:32 PM
SBTX Silverback Therapeutics, Inc. daily Stock Chart
SBTX [NASD]
Silverback Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own1.40% Shs Outstand35.05M Perf Week7.59%
Market Cap112.26M Forward P/E- EPS next Y-1.49 Insider Trans0.47% Shs Float34.06M Perf Month-5.17%
Income-89.50M PEG- EPS next Q-0.54 Inst Own91.60% Short Float3.56% Perf Quarter-25.54%
Sales- P/S- EPS this Y-169.80% Inst Trans-0.65% Short Ratio2.93 Perf Half Y-63.38%
Book/sh8.95 P/B0.35 EPS next Y-21.90% ROA-22.00% Target Price3.43 Perf Year-89.15%
Cash/sh7.06 P/C0.44 EPS next 5Y- ROE-23.20% 52W Range2.80 - 35.63 Perf YTD-53.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-90.99% Beta-
Dividend %- Quick Ratio17.60 Sales past 5Y- Gross Margin- 52W Low14.64% ATR0.18
Employees90 Current Ratio17.60 Sales Q/Q- Oper. Margin- RSI (14)51.11 Volatility6.01% 5.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-102.60% Profit Margin- Rel Volume0.45 Prev Close3.12
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume414.05K Price3.21
Recom1.60 SMA203.35% SMA50-5.06% SMA200-63.66% Volume140,031 Change2.88%
Apr-04-22Downgrade Goldman Buy → Neutral $25 → $3.50
Apr-01-22Downgrade SVB Leerink Outperform → Mkt Perform $25 → $1.80
Apr-01-22Downgrade Stifel Buy → Hold $32 → $6
Apr-01-22Downgrade H.C. Wainwright Buy → Neutral
Dec-29-20Initiated SVB Leerink Outperform $40
Dec-29-20Initiated Stifel Buy $58
Dec-29-20Initiated H.C. Wainwright Buy $44
Dec-29-20Initiated Goldman Buy $43
May-17-22 04:05PM  
May-12-22 04:01PM  
May-08-22 10:20AM  
Mar-31-22 04:00PM  
Feb-24-22 04:30PM  
Feb-03-22 04:05PM  
09:38AM  
Jan-05-22 09:00AM  
Dec-31-21 07:43PM  
05:51PM  
02:40PM  
08:40AM  
Dec-30-21 02:41PM  
12:00PM  
11:00AM  
10:30AM  
08:40AM  
Dec-29-21 10:10PM  
05:54PM  
03:33PM  
02:40PM  
09:00AM  
Dec-28-21 05:54PM  
01:44PM  
08:45AM  
07:00AM  
Dec-27-21 08:30PM  
05:51PM  
12:33PM  
09:45AM  
Dec-26-21 05:30PM  
08:13AM  
Dec-24-21 10:05AM  
Dec-23-21 08:45PM  
06:41PM  
05:00PM  
08:30AM  
Dec-22-21 04:45PM  
08:30AM  
Dec-21-21 10:06PM  
09:52PM  
06:49PM  
06:25PM  
Dec-20-21 10:12PM  
05:54PM  
09:40AM  
08:45AM  
Dec-19-21 09:28PM  
09:00PM  
08:13AM  
Dec-17-21 01:20PM  
12:00PM  
08:45AM  
Dec-16-21 06:41PM  
06:18PM  
04:00PM  
09:45AM  
08:15AM  
Dec-15-21 06:23PM  
01:40PM  
Dec-14-21 09:08PM  
09:00PM  
11:00AM  
10:40AM  
Dec-13-21 11:00PM  
02:40PM  
09:15AM  
Dec-10-21 07:05PM  
06:15PM  
03:30PM  
01:15PM  
Dec-09-21 09:00PM  
04:50PM  
11:00AM  
Dec-08-21 10:00AM  
Dec-07-21 05:19PM  
04:15PM  
02:10PM  
01:15PM  
11:00AM  
Dec-06-21 05:32PM  
04:05PM  
Dec-05-21 03:24PM  
Dec-04-21 05:00AM  
Dec-03-21 07:58PM  
02:46PM  
01:15PM  
12:00PM  
09:15AM  
Dec-02-21 11:36PM  
06:55PM  
04:45PM  
10:22AM  
08:45AM  
Dec-01-21 08:25PM  
06:54PM  
05:26PM  
03:45PM  
10:40AM  
09:10AM  
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROOT JONATHAN DDirectorNov 15Buy8.852,01417,8242,364Mar 18 05:14 PM
NARI Inari Medical, Inc. daily Stock Chart
NARI [NASD]
Inari Medical, Inc.
Index- P/E- EPS (ttm)-0.02 Insider Own3.10% Shs Outstand50.95M Perf Week15.27%
Market Cap2.92B Forward P/E- EPS next Y-0.23 Insider Trans-20.29% Shs Float45.15M Perf Month-35.94%
Income-0.80M PEG- EPS next Q-0.24 Inst Own85.00% Short Float5.40% Perf Quarter-24.81%
Sales306.30M P/S9.52 EPS this Y-33.80% Inst Trans1.48% Short Ratio2.94 Perf Half Y-33.31%
Book/sh8.22 P/B7.31 EPS next Y58.80% ROA-0.20% Target Price111.67 Perf Year-28.04%
Cash/sh6.98 P/C8.61 EPS next 5Y44.70% ROE-0.30% 52W Range50.50 - 100.00 Perf YTD-34.16%
Dividend- P/FCF- EPS past 5Y- ROI4.20% 52W High-39.91% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin90.20% 52W Low18.99% ATR5.84
Employees800 Current Ratio11.60 Sales Q/Q51.20% Oper. Margin0.00% RSI (14)37.99 Volatility7.95% 8.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-145.80% Profit Margin-0.20% Rel Volume0.70 Prev Close60.09
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume828.61K Price60.09
Recom1.40 SMA20-14.78% SMA50-25.58% SMA200-26.94% Volume431,848 Change0.00%
Mar-23-22Resumed BofA Securities Buy $105
Dec-15-20Upgrade Wells Fargo Equal Weight → Overweight $79
Nov-18-20Initiated BTIG Research Buy $92
Oct-29-20Upgrade Morgan Stanley Equal-Weight → Overweight $66 → $76
Sep-28-20Initiated SVB Leerink Outperform $80
Jun-19-20Initiated Canaccord Genuity Buy
Jun-16-20Initiated Wells Fargo Equal Weight $49
Jun-16-20Initiated Morgan Stanley Equal-Weight $52
Jun-16-20Initiated BofA/Merrill Neutral $56
May-13-22 04:01PM  
May-06-22 12:16PM  
May-05-22 09:56AM  
03:00AM  
May-04-22 05:35PM  
04:01PM  
May-02-22 03:48AM  
Apr-28-22 07:54PM  
04:01PM  
Apr-20-22 04:01PM  
Apr-04-22 02:51PM  
Mar-25-22 11:30AM  
Mar-21-22 05:27PM  
Mar-10-22 09:07PM  
07:33AM  
Mar-01-22 08:00AM  
Feb-28-22 10:16AM  
Feb-24-22 01:30AM  
Feb-23-22 04:01PM  
Feb-15-22 08:00AM  
Feb-10-22 04:01PM  
Feb-03-22 09:26AM  
Feb-01-22 04:01PM  
Jan-31-22 05:38PM  
Jan-11-22 05:54AM  
Jan-10-22 04:01PM  
Dec-29-21 04:01PM  
Dec-20-21 08:13AM  
Dec-17-21 07:15PM  
11:39AM  
Dec-16-21 05:38PM  
Dec-15-21 05:46AM  
Dec-09-21 10:15AM  
Nov-29-21 03:04PM  
06:57AM  
Nov-10-21 07:32AM  
05:02AM  
Nov-09-21 06:15PM  
04:01PM  
Nov-03-21 11:03AM  
Nov-02-21 03:02PM  
Oct-28-21 08:01AM  
Oct-26-21 04:01PM  
Oct-21-21 11:18AM  
Oct-20-21 08:00AM  
Oct-18-21 08:00AM  
04:20AM  
Oct-04-21 11:51AM  
10:57AM  
Oct-01-21 08:00AM  
Sep-29-21 10:25AM  
Sep-21-21 08:00AM  
Sep-16-21 07:07AM  
Sep-13-21 11:47AM  
Sep-09-21 11:30AM  
06:03AM  
Sep-08-21 08:32PM  
Sep-03-21 11:12AM  
Aug-30-21 06:36AM  
Aug-26-21 04:01PM  
Aug-24-21 07:10AM  
Aug-18-21 02:23PM  
09:40AM  
Aug-11-21 12:13PM  
09:01AM  
06:22AM  
12:31AM  
Aug-10-21 05:35PM  
04:01PM  
07:20AM  
Aug-03-21 06:00PM  
03:00PM  
Jul-29-21 04:01PM  
Jul-28-21 06:15AM  
Jul-27-21 04:01PM  
Jul-21-21 04:42AM  
Jul-19-21 02:48PM  
Jun-22-21 08:00AM  
Jun-15-21 05:00AM  
Jun-07-21 08:00AM  
May-26-21 02:00PM  
May-23-21 06:25AM  
May-20-21 06:10AM  
May-12-21 02:01AM  
May-11-21 04:01PM  
02:30PM  
May-10-21 08:25AM  
08:03AM  
May-04-21 08:00AM  
Apr-29-21 04:01PM  
04:49AM  
Apr-27-21 04:01PM  
Apr-14-21 08:00AM  
Apr-05-21 08:00AM  
Mar-28-21 06:40AM  
Mar-25-21 07:00AM  
Mar-14-21 06:25AM  
Mar-13-21 06:33AM  
Mar-10-21 11:45PM  
03:00PM  
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hill, Mitch C.Chief Financial OfficerMay 16Option Exercise0.467,5003,42887,062May 18 04:40 PM
Hill, Mitch C.Chief Financial OfficerMay 16Sale59.147,500443,53379,562May 18 04:40 PM
Tu ThomasChief Medical OfficerMay 10Option Exercise0.4630,00013,710107,819May 12 05:51 PM
Hoffman WilliamPresident and CEOMay 05Option Exercise0.4330,00012,840576,319May 09 04:30 PM
Hoffman WilliamPresident and CEOMay 05Sale72.7930,0002,183,640550,307May 09 04:30 PM
Hykes AndrewChief Operating OfficerMay 02Sale79.675,000398,351151,984May 04 04:33 PM
Hill, Mitch C.Chief Financial OfficerApr 18Option Exercise0.467,5003,42887,062Apr 20 05:57 PM
MILDER DONALD BDirectorApr 18Sale86.897,000608,2033,654,614Apr 20 05:58 PM
Hill, Mitch C.Chief Financial OfficerApr 18Sale86.897,500651,65079,562Apr 20 05:57 PM
Hoffman WilliamPresident and CEOApr 05Option Exercise0.4330,00012,840580,307Apr 07 04:34 PM
Hoffman WilliamPresident and CEOApr 05Sale90.2530,0002,707,626550,307Apr 07 04:34 PM
Hykes AndrewChief Operating OfficerApr 01Sale91.1610,000911,578156,984Apr 05 04:38 PM
Tu ThomasChief Medical OfficerMar 28Option Exercise0.462,00091480,274Mar 30 04:33 PM
Tu ThomasChief Medical OfficerMar 28Sale90.002,000180,00078,499Mar 30 04:33 PM
Hykes AndrewChief Operating OfficerMar 16Option Exercise0.4310,0004,284167,977Mar 18 05:08 PM
MILDER DONALD BDirectorMar 16Sale80.187,000561,260237,203Mar 18 05:08 PM
Hill, Mitch C.Chief Financial OfficerMar 15Option Exercise0.467,5003,42895,224Mar 17 06:02 PM
Hill, Mitch C.Chief Financial OfficerMar 15Sale75.547,500566,54887,724Mar 17 06:02 PM
Hoffman WilliamPresident and CEOMar 07Option Exercise0.4330,00012,852568,687Mar 09 05:08 PM
Hoffman WilliamPresident and CEOMar 07Sale95.4860,0005,728,859508,687Mar 09 05:08 PM
Tu ThomasChief Medical OfficerMar 01Option Exercise0.462178,276Mar 02 06:24 PM
Tu ThomasChief Medical OfficerMar 01Sale90.00218078,274Mar 02 06:24 PM
Hykes AndrewChief Operating OfficerMar 01Sale90.4913,6961,239,402157,977Mar 02 06:24 PM
Tu ThomasChief Medical OfficerFeb 28Option Exercise0.463,9981,82382,272Mar 02 06:24 PM
Tu ThomasChief Medical OfficerFeb 28Sale90.013,998359,88078,274Mar 02 06:24 PM
Hykes AndrewChief Operating OfficerFeb 28Sale90.056,304567,676171,673Mar 02 06:24 PM
MILDER DONALD BDirectorFeb 24Sale80.064,172333,9983,878,614Feb 25 05:52 PM
MILDER DONALD BDirectorFeb 23Sale80.001008,0003,882,786Feb 25 05:52 PM
MILDER DONALD BDirectorFeb 16Sale80.068,993719,9803,882,886Feb 17 06:42 PM
Hill, Mitch C.Chief Financial OfficerFeb 15Option Exercise0.467,5003,42875,288Feb 17 06:41 PM
Hill, Mitch C.Chief Financial OfficerFeb 15Sale79.107,500593,24367,788Feb 17 06:41 PM
MILDER DONALD BDirectorFeb 15Sale80.0133526,8033,891,879Feb 17 06:42 PM
MILDER DONALD BDirectorFeb 09Sale80.0640032,0243,892,214Feb 11 07:39 PM
Hoffman WilliamPresident and CEOFeb 07Option Exercise0.4330,00012,840566,867Feb 09 07:57 PM
Hoffman WilliamPresident and CEOFeb 07Sale74.0130,0002,220,395538,687Feb 09 07:57 PM
Hill, Mitch C.Chief Financial OfficerJan 18Option Exercise0.467,5003,42874,941Jan 20 08:05 PM
Hykes AndrewChief Operating OfficerJan 18Sale76.655,000383,244152,979Jan 20 08:50 PM
Hill, Mitch C.Chief Financial OfficerJan 18Sale76.677,500575,01567,788Jan 20 08:05 PM
Hoffman WilliamPresident and CEOJan 04Sale94.0530,0002,821,455449,821Jan 06 07:22 PM
Hill, Mitch C.Chief Financial OfficerDec 15Sale79.0420,0001,580,74467,715Dec 17 05:49 PM
MILDER DONALD BDirectorDec 10Sale79.007,000553,0314,522,614Dec 13 05:42 PM
Hoffman WilliamPresident and CEODec 06Sale78.6360,0004,717,568480,369Dec 08 06:40 PM
Tu ThomasChief Medical OfficerNov 29Option Exercise0.465,0002,28563,612Dec 01 07:36 PM
Tu ThomasChief Medical OfficerNov 29Sale83.405,000416,99458,612Dec 01 07:36 PM
Tu ThomasChief Medical OfficerNov 15Option Exercise3.4610,00034,55858,612Nov 17 06:41 PM
ROOT JONATHAN DDirectorNov 15Buy89.0830326,992335Mar 18 05:10 PM
MILDER DONALD BDirectorNov 10Sale92.567,000647,9414,529,614Nov 12 05:09 PM
Hill, Mitch C.Chief Financial OfficerNov 09Option Exercise0.465,0002,28592,715Nov 12 05:10 PM
Hill, Mitch C.Chief Financial OfficerNov 09Sale86.825,000434,09587,715Nov 12 05:10 PM
Hoffman WilliamPresident and CEONov 05Sale91.2230,0002,736,611540,369Nov 09 04:30 PM
Hoffman WilliamPresident and CEOOct 28Sale90.173,722335,628570,369Oct 28 09:44 PM
Tu ThomasChief Medical OfficerOct 27Option Exercise0.465,0002,28553,612Oct 28 09:43 PM
Tu ThomasChief Medical OfficerOct 27Sale87.685,000438,37648,612Oct 28 09:43 PM
Hoffman WilliamPresident and CEOOct 25Sale90.0550045,027574,091Oct 27 04:56 PM
Hoffman WilliamPresident and CEOOct 20Sale90.1025,7782,322,724574,591Oct 21 05:54 PM
Hykes AndrewChief Operating OfficerOct 19Sale87.769,000789,878159,827Oct 20 08:29 PM
Hill, Mitch C.Chief Financial OfficerOct 08Option Exercise0.465,0002,28592,715Oct 12 04:49 PM
MILDER DONALD BDirectorOct 08Sale79.337,000555,3094,536,614Oct 12 04:49 PM
Hill, Mitch C.Chief Financial OfficerOct 08Sale79.315,000396,56687,715Oct 12 04:49 PM
Hoffman WilliamPresident and CEOOct 07Sale81.0929,9002,424,734600,369Oct 07 08:28 PM
Hoffman WilliamPresident and CEOOct 06Sale80.001008,000630,269Oct 06 05:48 PM
Hoffman WilliamPresident and CEOOct 05Sale78.9670,0005,527,370630,369Oct 06 05:48 PM
Tu ThomasChief Medical OfficerSep 27Option Exercise0.465,0002,28553,852Sep 28 08:12 PM
Tu ThomasChief Medical OfficerSep 27Sale82.865,000414,31148,852Sep 28 08:12 PM
Hykes AndrewChief Operating OfficerSep 17Sale80.759,000726,742169,174Sep 17 07:57 PM
MILDER DONALD BDirectorSep 10Sale81.027,000567,1674,543,614Sep 10 06:59 PM
Hill, Mitch C.Chief Financial OfficerSep 09Option Exercise0.465,0002,28592,946Sep 10 06:58 PM
Hill, Mitch C.Chief Financial OfficerSep 09Sale82.005,000409,98287,946Sep 10 06:58 PM
Hoffman WilliamPresident and CEOSep 07Sale81.5730,0002,447,099700,831Sep 08 03:06 PM
Tu ThomasChief Medical OfficerAug 27Option Exercise0.465,0002,28553,852Aug 30 05:39 PM
Tu ThomasChief Medical OfficerAug 27Sale81.315,000406,53448,852Aug 30 05:39 PM
Hykes AndrewChief Operating OfficerAug 19Sale72.669,000653,916178,174Aug 19 07:43 PM
Hykes AndrewChief Operating OfficerAug 18Option Exercise0.4320,0008,568198,174Aug 20 06:25 PM
Hill, Mitch C.Chief Financial OfficerAug 18Option Exercise0.4620,0009,14087,946Aug 20 06:24 PM
MILDER DONALD BDirectorAug 10Sale90.647,000634,4974,550,614Aug 11 05:17 PM
Hill, Mitch C.Chief Financial OfficerAug 09Option Exercise0.465,0002,28572,706Aug 10 01:35 PM
Hill, Mitch C.Chief Financial OfficerAug 09Sale95.165,000475,78967,946Aug 10 01:35 PM
Hoffman WilliamPresident and CEOAug 05Sale93.3330,0002,799,974730,831Aug 06 01:13 PM
Tu ThomasChief Medical OfficerJul 27Option Exercise0.465,0002,28553,852Jul 28 01:28 PM
Tu ThomasChief Medical OfficerJul 27Sale84.205,000421,02248,852Jul 28 01:28 PM
Hykes AndrewChief Operating OfficerJul 19Sale85.219,000766,871187,174Jul 20 07:21 PM
Hill, Mitch C.Chief Financial OfficerJul 09Option Exercise0.465,0002,28572,706Jul 12 07:44 PM
Hill, Mitch C.Chief Financial OfficerJul 09Sale92.715,000463,53567,706Jul 12 07:44 PM
MILDER DONALD BDirectorJul 09Sale92.727,000649,0424,557,614Jul 12 07:44 PM
Hoffman WilliamPresident and CEOJul 07Sale91.4869,9156,395,653760,596Jul 07 08:41 PM
Hoffman WilliamPresident and CEOJul 06Sale94.2260,0855,661,068830,973Jul 07 04:46 PM
Tu ThomasChief Medical OfficerJun 28Option Exercise0.465,0002,28554,092Jun 29 08:09 PM
Tu ThomasChief Medical OfficerJun 28Sale95.945,000479,68849,092Jun 29 08:09 PM
Hykes AndrewChief Operating OfficerJun 21Sale91.411,00191,505203,710Jun 21 02:01 PM
Hykes AndrewChief Operating OfficerJun 18Sale92.297,999738,260196,611Jun 21 02:01 PM
MILDER DONALD BDirectorJun 10Sale90.547,000633,7844,564,614Jun 11 03:20 PM
Hill, Mitch C.Chief Financial OfficerJun 09Option Exercise0.465,0002,28572,937Jun 09 06:06 PM
Hill, Mitch C.Chief Financial OfficerJun 09Sale90.435,000452,16167,937Jun 09 06:06 PM
Hoffman WilliamPresident and CEOJun 04Sale83.6630,0002,509,698891,058Jun 04 07:03 PM
Tu ThomasChief Medical OfficerMay 27Option Exercise0.055,00022854,092May 28 05:06 PM
Nielsen Kirk G.DirectorMay 27Option Exercise0.002,982049,302May 28 07:39 PM
MILDER DONALD BDirectorMay 27Option Exercise0.002,9820242,823May 28 06:37 PM
ROOT JONATHAN DDirectorMay 27Option Exercise0.002,9820524,846May 28 06:37 PM
Tu ThomasChief Medical OfficerMay 27Sale88.325,000441,57649,092May 28 05:06 PM
Tu ThomasChief Medical OfficerMay 25Option Exercise0.0510,00045749,092May 26 07:15 PM